Press Releases

Date	Title	Company
26-Jan-2021	Calibre Scientific Expands European Presence and Chromatography Offering With AIT France Acquisition	Calibre Scientific
26-Jan-2021	New antimicrobial polymers as alternatives to antibiotics	Emmy Noether Group
26-Jan-2021	MOBILion Systems and Protein Metrics join forces to integrate the Byos® Software Suite	MOBILion Systems
26-Jan-2021	Moderna COVID-19 Vaccine Retains Neutralizing Activity Against Emerging Variants First Identified in the U.K. and the Republic of South Africa	Moderna
26-Jan-2021	Moderna to Host Conference Call on COVID-19 Variants Announcement on Monday, Jan. 25	Moderna
26-Jan-2021	Dante Labs £30M investment in Cambridge will support global COVID-19 sequencing surveillance program	Dante Labs
26-Jan-2021	BioMed X Institute Starts New Research Project in Drug Delivery in Collaboration with Janssen	BioMed X
26-Jan-2021	First Patient Treated in Phase II Combination Trial of ISA Pharmaceuticals’ Lead Immunotherapy ISA101b with Keytruda®	ISA Pharmaceuticals B.V.
26-Jan-2021	Panthera continues to sign up new clinical trials across its UK network of dedicated clinical trial sites	Panthera
26-Jan-2021	TriRadial Solutions Names Michael Jensen Managing Director of Client Services	Newswire
26-Jan-2021	InstantGMP™ Adds Learning Management System to InstantGMP™ PRO	Newswire
26-Jan-2021	Orphan Drug Designation granted to rezafungin in EU for the treatment of invasive candidiasis	Mundipharma
26-Jan-2021	NEW MAGNETIC RESONANCE IMAGING (MRI) TECHNIQUE UNCOVERS PATHOPHYSIOLOGICAL PROCESS TO HELP EARLY DETECTION OF RECURRENT GLIOBLASTOMA	Karl Landsteiner University of Health Sciences
26-Jan-2021	ViiV Healthcare announces FDA approval of Cabenuva (cabotegravir, rilpivirine), the first and only complete long-acting regimen for HIV treatment	ViiV Healthcare
26-Jan-2021	BC Platforms, RIKEN and the Finnish Institute for Health and Welfare (THL) collaborate on artificial intelligence approach to identify people most at risk of from COVID-19	BC Platforms
26-Jan-2021	Investigating new treatment for schizophrenia as first Psychiatry Consortium funded project announced	Earlham Institute
26-Jan-2021	European Commission Approves AbbVie’s RINVOQTM (Upadacitinib) for the Treatment of Psoriatic Arthritis and Ankylosing Spondylitis	AbbVie
26-Jan-2021	BC Platforms, RIKEN and the Finnish Institute for Health and Welfare (THL) collaborate on artificial intelligence approach to identify people most at risk of from COVID-19	BC Platforms
26-Jan-2021	86% of Doctors Believe Mental Health Issues, Depression Will be the Biggest non-COVID-19 Issue as a Result of the Pandemic	B3C newswire
26-Jan-2021	European Commission Approves AbbVie’s RINVOQTM (Upadacitinib) for the Treatment of Psoriatic Arthritis and Ankylosing Spondylitis	AbbVie